中医药治疗肝硬化:细胞自噬机制
本文综述细胞自噬在肝硬化发生发展中的作用及中医药调控自噬防治肝硬化的机制。自噬与LC3、Beclin-1、P62、mTOR等蛋白及PI3K/Akt/mTOR、Ras/Raf/MEK/ERK、AMPK/mTOR等信号通路密切相关;中药单体与复方可调控上述通路和关键自噬蛋白,抑制肝星状细胞活化、减少细胞外基质沉积,发挥抗肝硬化作用,且不良反应较少、可能降低复发风险。
要点
- 自噬相关蛋白LC3、Beclin-1、P62、mTOR及PI3K/Akt/mTOR等通路参与肝硬化进展。
- 中药单体与复方通过调控自噬抑制肝星状细胞活化、减少细胞外基质沉积。
- 中医药治疗肝硬化不良反应较少,并可能降低疾病复发风险。
核心结论
- 中医药可通过调控细胞自噬相关信号通路和关键蛋白,抑制肝星状细胞活化、减少细胞外基质沉积,发挥抗肝硬化作用。
- 中医药在肝硬化治疗中不良反应较少,并可能降低疾病复发风险。
研究设计与样本
- 本文为综述,围绕细胞自噬在肝硬化防治中的作用及中医药调控自噬的机制进行汇总分析。
主要发现
- 细胞自噬是溶酶体介导的降解过程,与LC3、Beclin-1、P62、mTOR等蛋白密切相关。
- 自噬受PI3K/Akt/mTOR、Ras/Raf/MEK/ERK、AMPK/mTOR等信号通路调控。
- 自噬与凋亡、自噬与外泌体之间的关系已获进一步证实。
- 中药单体与复方可调控上述自噬相关通路及LC3、Beclin-1等关键蛋白,抑制肝星状细胞活化并减少细胞外基质沉积。
临床怎么用
- 临床可关注中药单体与复方通过调控自噬通路(如PI3K/Akt/mTOR、AMPK/mTOR)治疗肝硬化的潜在应用。
- 应用中医药治疗肝硬化时,可考虑其不良反应较少及可能降低复发风险的特点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver cirrhosis is a critical stage in the progression of various chronic liver diseases, often leading to severe complications such as ascites, hepatic encephalopathy, and a high mortality rate, and it thus poses a serious threat to patient life. The activation of hepatic stellate cells is a central driver of disease progression. Cellular autophagy, a lysosome-mediated degradation process, plays a key role in maintaining cellular function and dynamic homeostasis. Research has shown that autophagy is closely associated with proteins like LC3, Beclin-1, P62, and mTOR, and is regulated through signaling pathways such as PI3K/Akt/mTOR, Ras/Raf/MEK/ERK, and AMPK/mTOR. Additionally, the relationship between autophagy and apoptosis, as well as between autophagy and exosomes, has been further demonstrated. While modern medicine has made progress in treating cirrhosis, it still faces significant limitations. By contrast, numerous studies have demonstrated the efficacy of traditional Chinese medicine in preventing and treating liver cirrhosis by regulating autophagy, with fewer adverse effects. Chinese herbal monomers and formulations can modulate various autophagy-related signaling pathways, including PI3K/Akt/mTOR, Ras/Raf/MEK/ERK, and AMPK/mTOR, and influence key autophagy proteins such as LC3 and Beclin-1. This modulation inhibits hepatic stellate cell activation, reduces extracellular matrix deposition, and exerts anticirrhotic effects. Moreover, Chinese medicine appears to reduce adverse reactions in cirrhosis treatment and lower the risk of disease recurrence. This review explores the mechanisms of autophagy in the prevention and treatment of liver cirrhosis through Chinese medicine, offering new insights for the development of Chinese medicinal therapies for cirrhosis and their rational clinical application.
引用
- Zheng S, Xue T, Wang Q, et al. Chinese Medicine for the Treatment of Liver Cirrhosis: The Mechanism of Cellular Autophagy. Am J Chin Med. 2025. PMID: 40070295. doi:10.1142/S0192415X25500168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。